Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply

Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply

Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures, and sells a diversified range of instrumentation, consumables, and services. The Company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research. Its proprietary multi-omics tools provide unique insights into human health, immune response, and disease states across a broad range of applications, including proteomics and genomics, and other areas of translational and clinical research. The Company's solutions are designed to unlock complex biological information across plasma, single-cell, and spatial proteomics, as well as genomic analyses, enabling researchers to explore disease mechanisms with unprecedented depth and precision. Its advanced platforms are CyTOF and Hyperion.
Market Capitalisation
$242.28M
Price-earnings ratio
-
Dividend yield
0.00%
Volume
2.81M
High today
$0.65
Low today
$0.57
Open price
$0.63
52-week high
$1.72
52-week low
$0.39
Ready to start your investing journey with Stake?
Open an accountThis is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in LAB on Stake
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.